GSK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding. GlaxoSmithKline PLC's share price for the quarter that ended in Dec. 2014 was $0. GlaxoSmithKline PLC's shares outstanding for the quarter that ended in Dec. 2014 was 2,406 Mil. Therefore, GlaxoSmithKline PLC's market cap for the quarter that ended in Dec. 2014 was $106,825 Mil.
GlaxoSmithKline PLC's quarterly market cap declined from Jun. 2014 ($128,459 Mil) to Sep. 2014 ($110,420 Mil) and declined from Sep. 2014 ($110,420 Mil) to Dec. 2014 ($0 Mil).
GlaxoSmithKline PLC's annual market cap declined from Dec. 2011 ($115,171 Mil) to Dec. 2012 ($106,559 Mil) but then increased from Dec. 2012 ($106,559 Mil) to Dec. 2013 ($129,748 Mil).
Enterprise value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. GlaxoSmithKline PLC's enterprise value for Today is $265,513 Mil.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
GlaxoSmithKline PLC's Market Cap for the fiscal year that ended in Dec. 2013 is calculated as
|Market Cap (A: Dec. 2013 )||=||Share Price (A: Dec. 2013 )||*||Shares Outstanding (A: Dec. 2013 )|
GlaxoSmithKline PLC's Market Cap for the quarter that ended in Dec. 2014 is calculated as
|Market Cap (Q: Dec. 2014 )||=||Share Price (Q: Dec. 2014 )||*||Shares Outstanding (Q: Dec. 2014 )|
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
GlaxoSmithKline PLC Annual Data
GlaxoSmithKline PLC Quarterly Data